Post by gMendel

gMendel® today announced the successful closing of its seed funding round and a strategic investment of DKK 9 million from Metavallon VC to accelerate the global deployment of its technology across Latin America, the Middle East, and Africa. The agreement follows over a year of rigorous evaluation, including extensive due diligence and consultations with international experts and healthcare professionals, confirming strong confidence in gMendel®’s technology and impact potential. Our CEO, Chris Kyriakidis, said: “This investment marks a pivotal milestone for gMendel®. It validates not only our technology, but the urgent global need for scalable genetic screening solutions. Together with Metavallon VC, we are accelerating our mission to make early, accurate diagnosis accessible to every newborn, regardless of geography. By combining genomics and AI, we have the opportunity to fundamentally change how healthcare systems detect and manage genetic disorders, ultimately saving lives while significantly reducing long-term costs.” George Karantonis, Partner at Metavallon VC, added: "We believe gMendel® is uniquely positioned to drive the next generation of genetic screening and improve outcomes at population scale. Having followed the team closely over an extended period, we have been consistently impressed not only by the strength of the technology, but by their commitment and strong internal drive to translate innovation into tangible societal impact. In addition, gMendel®’s plans to establish a technology development hub in Greece, along with the initiation of discussions with the Greek Ministry of Health for potential adoption of the solution, further strengthen our conviction in the company’s long‑term vision and make this investment even more relevant to our strategy." This partnership marks a major milestone in our mission to reduce infant mortality and transform global healthcare through early, data-driven screening at population scale. 👉 Read the full announcement: https://lnkd.in/euMQEPsQ #HealthTech #Genomics #Genetics #RareDiseases #GeneticDisorders #Screening #Diagnostics #Healthcare #Innovation #NBS #AI #ArtificialIntelligence #MachineLearning #VentureCapital #VC #Commercialization